Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
VNDA's Cash-to-Debt is ranked higher than
93% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. VNDA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
VNDA' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.53  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.62
VNDA's Equity-to-Asset is ranked lower than
55% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. VNDA: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
VNDA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.19 Max: 0.94
Current: 0.62
0.01
0.94
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
91% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VNDA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 5.04
Beneish M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -7.13
VNDA's Operating Margin % is ranked higher than
66% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. VNDA: -7.13 )
Ranked among companies with meaningful Operating Margin % only.
VNDA' s Operating Margin % Range Over the Past 10 Years
Min: -790.41  Med: -35.4 Max: 40
Current: -7.13
-790.41
40
Net Margin % -6.54
VNDA's Net Margin % is ranked higher than
66% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. VNDA: -6.54 )
Ranked among companies with meaningful Net Margin % only.
VNDA' s Net Margin % Range Over the Past 10 Years
Min: -788.46  Med: -33.81 Max: 40.25
Current: -6.54
-788.46
40.25
ROE % -7.96
VNDA's ROE % is ranked higher than
68% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. VNDA: -7.96 )
Ranked among companies with meaningful ROE % only.
VNDA' s ROE % Range Over the Past 10 Years
Min: -134.08  Med: -52.74 Max: 23.67
Current: -7.96
-134.08
23.67
ROA % -4.93
VNDA's ROA % is ranked higher than
70% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. VNDA: -4.93 )
Ranked among companies with meaningful ROA % only.
VNDA' s ROA % Range Over the Past 10 Years
Min: -111.28  Med: -16.55 Max: 12.81
Current: -4.93
-111.28
12.81
ROC (Joel Greenblatt) % -221.31
VNDA's ROC (Joel Greenblatt) % is ranked higher than
53% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. VNDA: -221.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VNDA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4620.09  Med: -1029.58 Max: 784.55
Current: -221.31
-4620.09
784.55
3-Year Revenue Growth Rate 44.40
VNDA's 3-Year Revenue Growth Rate is ranked higher than
85% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. VNDA: 44.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VNDA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.85 Max: 90.4
Current: 44.4
0
90.4
3-Year EBITDA Growth Rate -37.60
VNDA's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. VNDA: -37.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VNDA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.3 Max: 22.5
Current: -37.6
0
22.5
3-Year EPS without NRI Growth Rate -15.90
VNDA's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. VNDA: -15.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VNDA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.5 Max: -2.4
Current: -15.9
GuruFocus has detected 4 Warning Signs with Vanda Pharmaceuticals Inc $VNDA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VNDA's 30-Y Financials

Financials (Next Earnings Date: 2018-01-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

VNDA Guru Trades in Q3 2016

Steven Cohen 542,700 sh (New)
Paul Tudor Jones 48,953 sh (+284.88%)
Jim Simons 432,050 sh (+186.03%)
Joel Greenblatt 27,244 sh (+90.46%)
John Paulson 2,175,000 sh (-43.72%)
» More
Q4 2016

VNDA Guru Trades in Q4 2016

Joel Greenblatt 60,217 sh (+121.03%)
Jim Simons 568,350 sh (+31.55%)
Paul Tudor Jones 50,547 sh (+3.26%)
John Paulson Sold Out
Steven Cohen 151,100 sh (-72.16%)
» More
Q1 2017

VNDA Guru Trades in Q1 2017

Steven Cohen 2,484,500 sh (+1544.28%)
Joel Greenblatt 167,953 sh (+178.91%)
Jim Simons 939,250 sh (+65.26%)
Paul Tudor Jones 43,658 sh (-13.63%)
» More
Q2 2017

VNDA Guru Trades in Q2 2017

Jim Simons 1,097,950 sh (+16.90%)
Joel Greenblatt 173,923 sh (+3.55%)
Steven Cohen 1,942,400 sh (-21.82%)
Paul Tudor Jones 29,811 sh (-31.72%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 3.55%$13.45 - $16.55 $ 18.8531%173,923
Joel Greenblatt 2017-03-31 Add 178.91%0.02%$13.05 - $15.95 $ 18.8532%167,953
Joel Greenblatt 2016-12-31 Add 121.03%0.01%$13.65 - $17.63 $ 18.8517%60,217
John Paulson 2016-12-31 Sold Out 0.4%$13.65 - $17.63 $ 18.8517%0
John Paulson 2016-09-30 Reduce -43.72%0.2%$10.99 - $17.05 $ 18.8540%2,175,000
Joel Greenblatt 2016-09-30 Add 90.46%$10.99 - $17.05 $ 18.8540%27,244
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TGTX, NAS:NTLA, NAS:ANIK, NAS:AKBA, NAS:ADRO, NAS:RETA, NAS:PTCT, NAS:KERX, NAS:ITCI, NAS:SPPI, NAS:ENTA, NAS:BYSI, NAS:EDIT, NAS:RGNX, NAS:ZIOP, NAS:IMGN, NAS:CYTK, NAS:RVNC, NAS:GTHX, NAS:AMRI » details
Traded in other countries:VM4.Germany,
Headquarter Location:USA
Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs.

Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its key drug, Hetlioz, is an oral compound approved for the orphan indication of non-24-hour sleep-wake disorder. Vanda also developed Fanapt, which is approved for the treatment of schizophrenia. All of the firm's therapies were in-licensed from Big Pharma.

Ratios

vs
industry
vs
history
Forward PE Ratio 185.19
VNDA's Forward PE Ratio is ranked lower than
99.99% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. VNDA: 185.19 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.43
VNDA's PB Ratio is ranked lower than
65% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. VNDA: 6.43 )
Ranked among companies with meaningful PB Ratio only.
VNDA' s PB Ratio Range Over the Past 10 Years
Min: 2.53  Med: 5.56 Max: 623.46
Current: 6.43
2.53
623.46
PS Ratio 5.36
VNDA's PS Ratio is ranked higher than
72% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. VNDA: 5.36 )
Ranked among companies with meaningful PS Ratio only.
VNDA' s PS Ratio Range Over the Past 10 Years
Min: 2.63  Med: 5.76 Max: 70.3
Current: 5.36
2.63
70.3
EV-to-EBIT -63.61
VNDA's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. VNDA: -63.61 )
Ranked among companies with meaningful EV-to-EBIT only.
VNDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1288.6  Med: -2.35 Max: 578.2
Current: -63.61
-1288.6
578.2
EV-to-EBITDA -170.72
VNDA's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. VNDA: -170.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
VNDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -171.26  Med: -2.2 Max: 81.6
Current: -170.72
-171.26
81.6
EV-to-Revenue 4.57
VNDA's EV-to-Revenue is ranked higher than
78% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. VNDA: 4.57 )
Ranked among companies with meaningful EV-to-Revenue only.
VNDA' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.4  Med: 3.1 Max: 25.3
Current: 4.57
-1.4
25.3
Current Ratio 2.31
VNDA's Current Ratio is ranked lower than
71% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. VNDA: 2.31 )
Ranked among companies with meaningful Current Ratio only.
VNDA' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.53 Max: 18.62
Current: 2.31
1.67
18.62
Quick Ratio 2.30
VNDA's Quick Ratio is ranked lower than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. VNDA: 2.30 )
Ranked among companies with meaningful Quick Ratio only.
VNDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 4.53 Max: 18.62
Current: 2.3
1.64
18.62
Days Inventory 14.50
VNDA's Days Inventory is ranked higher than
90% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. VNDA: 14.50 )
Ranked among companies with meaningful Days Inventory only.
VNDA' s Days Inventory Range Over the Past 10 Years
Min: 14.5  Med: 151.44 Max: 596.04
Current: 14.5
14.5
596.04
Days Sales Outstanding 49.13
VNDA's Days Sales Outstanding is ranked higher than
69% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. VNDA: 49.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
VNDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.22  Med: 24.24 Max: 253.93
Current: 49.13
5.22
253.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.70
VNDA's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. VNDA: -9.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VNDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -6.35 Max: 0
Current: -9.7
-14.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.61
VNDA's Price-to-Net-Cash is ranked lower than
66% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. VNDA: 14.61 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VNDA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.31  Med: 8.51 Max: 1625
Current: 14.61
0.31
1625
Price-to-Net-Current-Asset-Value 8.85
VNDA's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. VNDA: 8.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VNDA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.3  Med: 7.38 Max: 185
Current: 8.85
0.3
185
Price-to-Tangible-Book 8.09
VNDA's Price-to-Tangible-Book is ranked lower than
65% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. VNDA: 8.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VNDA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.29  Med: 6.36 Max: 356.36
Current: 8.09
0.29
356.36
Price-to-Median-PS-Value 0.93
VNDA's Price-to-Median-PS-Value is ranked higher than
62% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. VNDA: 0.93 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VNDA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 0.99 Max: 11.6
Current: 0.93
0.51
11.6
Earnings Yield (Greenblatt) % -1.60
VNDA's Earnings Yield (Greenblatt) % is ranked higher than
66% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. VNDA: -1.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VNDA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19207.4  Med: -2.6 Max: 3521.3
Current: -1.6
-19207.4
3521.3

More Statistics

Revenue (TTM) (Mil) $156.20
EPS (TTM) $ -0.22
Beta0.76
Short Percentage of Float4.50%
52-Week Range $12.70 - 18.99
Shares Outstanding (Mil)44.86

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 171 201 234 273
EPS ($) -0.20 0.10 0.81 1.21
EPS without NRI ($) -0.20 0.10 0.81 1.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis Sep 13 2017 
Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences Sep 11 2017 
Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference Sep 06 2017 
Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fa Jul 21 2017 
Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 Jul 17 2017 
Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences Jun 05 2017 
Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference May 01 2017 
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 Apr 13 2017 
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors Mar 31 2017 
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 

More From Other Websites
These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Sep 19 2017
Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)? Sep 14 2017
Summit Therapeutics Stock Gets Smoked After IPO Pricing Sep 14 2017
Vanda Pharma shares decline as goal of itch drug study not reached Sep 13 2017
Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis Sep 13 2017
Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences Sep 11 2017
Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference Sep 06 2017
Edited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT Sep 01 2017
Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice Aug 29 2017
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR Aug 28 2017
5 Efficient Stocks to Buy for a Healthy Portfolio Aug 25 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US :... Aug 23 2017
Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : August 21, 2017 Aug 21 2017
Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3% Aug 16 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US :... Aug 09 2017
Vanda Pharmaceuticals preps for jet lag study results later this year Aug 04 2017
Vanda reports 2Q loss Aug 02 2017
Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results Aug 02 2017
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call Aug 02 2017
Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on... Jul 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}